Please assess the completion status of the following clinical trial:

Trial Title: A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent before starting any study-specific procedure. If any patient is unable to give consent, it may be obtained from the patient's legal representative if in accordance with local laws and regulations.~2. Men with castrate metastatic adenocarcinoma of the prostate, with the following characteristics:~   * Confirmed pathological diagnosis.~  * Metastatic disease (radiologically documented).~  * All patients with chemical castration must have a serum testosterone level below 50 ng/ml. There is no need to document a serum testosterone in patients having a prior surgical castration2.~  * Baseline PSA \> 5 ng/ml (according to the recommendations from the Prostate-Specific Antigen Working Group2).~  * Androgen-independent progressive disease, as defined by detectable, rising PSA in two consecutive measurements at least one week apart:~     * If PSA responded to a prior therapy, progression occurs when the PSA is 50% above the nadir level.~    * If PSA did not respond to a prior therapy, progression occurs when the PSA increases by 25% or more above pretreatment levels.~    * In both cases, the increase in absolute value PSA level must be at least 5 ng/ml, and must be confirmed by a second measurement a minimum of 1 week later.~  * Patients must have received prior docetaxel-based chemotherapy.~3. Recovery from any toxicity derived from previous treatments. The presence of alopecia and NCI-CTC grade \< 2 sensitive peripheral neuropathy is allowed.~4. Age \> 18 years.~5. Performance status (ECOG) \< 2.~6. Life expectancy \> 3 months.~7. Adequate renal, hepatic, and bone marrow function (assessed \< 14 days before inclusion in the study):~   * Neutrophil count ³ 1.5 x 109/L.~  * Platelet count ³ 100 x 109/L. Hemoglobin \> 9 g/dl.~  * Creatinine clearance ³ 40 ml/min (calculated from the Cockcroft and Gault formula), see Appendix 3.~  * Serum bilirubin \* 1.5 mg/dl.~  * AST, ALT \< 2.5 x ULN (\< 5 x ULN in case of liver metastasis).~  * Albumin \> 25 g/L.~8. Left ventricular ejection fraction within normal limits~Exclusion Criteria:~1. Prior therapy with Aplidin®.~2. Concomitant therapy with any anti-tumor agent, including glucocorticoids at a daily dose greater than 10 mg prednisone or equivalent, except when they were indicated for symptom control, provided that disease progression was documented while on steroids.~3. Small cell carcinoma of the prostate.~4. More than two previous lines of systemic therapy for patient's castrate metastatic disease, considering biological agents or chemotherapy as systemic therapy.~5. Patients with progressive measurable disease but without increased PSA value (according to the consensus recommendations) will not be considered eligible.~6. Wash-out periods less than:~   * 6 weeks after the last dose of a nitroso-urea or high dose chemotherapy~  * 4 weeks after the last dose of other chemotherapies or biological agents~  * 6 weeks after the end of treatment with extensive external beam radiation (more than 25% of bone marrow distribution) or radionuclide therapy.~  * 4 weeks after the end of treatment with palliative radiation involving less than 25% of bone marrow reserves.~  * 4 weeks for major prior surgery~  * 30 days after receiving any other investigational product~7. Men of reproductive potential who are not using effective contraceptive methods, considering complete abstinence from intercourse throughout the treatment with the study drug and for at least 6 months after completion or premature discontinuation from the study as an effective contraceptive method, to be sure that the patient's female partner does not become pregnant.~8. History of another neoplastic disease. The exceptions are:~   8.1 Non-melanoma skin cancer. 8.2 Any other cancer curatively treated with no evidence of disease for at least 10 years.~9. Known symptomatic cerebral or leptomeningeal involvement.~10. Other relevant diseases or adverse clinical conditions:~    * History or presence of unstable angina, myocardial infarction, valvular heart disease or congestive heart failure.~   * Previous mediastinal radiotherapy.~   * Uncontrolled arterial hypertension despite optimal medical therapy.~   * Previous treatment with doxorubicin at cumulative doses in excess of 400 mg/m².~   * Symptomatic arrhythmia or any arrhythmia requiring treatment.~   * Abnormal ECG as detailed below:~      * QT interval prolongation:~     * QTc\> 480 msec.~     * Left ventricular hypertrophy :~     * Sokolow Index: (R V5 or V6) + S V1)\> 3.5mv.~     * Left bundle-branch block:~     * Complete: QRS\> 0.12 sec. No Q wave is seen in leads V5 and V6. A notched R wave is seen in left leads and a notched S wave in right side leads.~     * Right bundle-branch block:~     * Complete: QRS\> 0.12 sec. Secondary R (R') wave in leads V1-V2. Slurred S wave in leads D1 ,avL, V5 and V6.~     * Second-degree atrioventricular (av) block:~     * Mobitz I AV block, or Wenckebach block: Progressive prolongation of the PR interval causing progressive R-R interval shortening until a P wave fails to conduct the ventricle. The RR interval containing the blocked P wave is shorter than the sum of the twPP interval.~     * Mobitz II AV block is characterized by sudden unexpected blocked P waves without variation or prolongation of the PR interval. It can be 2:1, 3:1, 4:1 etc.~     * Third-degree atrioventricular block:~     * P waves and QRS complexes without mutual relationship. P wave rate is greater than that of QRS complexes.~     * Ischemia, injury and infarction:~     * Subendocardial ischemia. - Symmetrical T waves of increased amplitude.~     * Subepicardial ischemia. - Inverted symmetrical T waves.~     * Subendocardial injury. - ST segment depression (horizontal or descending).~     * Subepicardial injury. - ST segment elevation with upper convexity.~     * Infarction or necrosis. - Q wave voltage greater than 25% of R wave voltage.~     * Duration of Q wave is 0.04 sec or more~   * History of significant neurological or psychiatric disorders.~   * Active infection; infection by HIV, HBV or HCV. HIV, HBV or HCV testing are not required unless infection is clinically suspected.~   * Myopathy or any clinical situation that causes significant and persistent elevation of CK (\> 2.5 ULN in two different determinations performed with one week apart).~   * Significant non-neoplastic liver disease (e.g., cirrhosis, active chronic hepatitis).~   * Limitation of the patient's ability to comply with the treatment or follow-up protocol.~   * Uncontrolled endocrine diseases (e.g. diabetes mellitus, hypothyroidism or hyperthyroidism) (i.e. requiring relevant changes in medication within the last month, or hospital admission within the last 3 months).~11. Known hypersensitivity to Aplidin®, mannitol, cremophor EL, or ethanol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Aplidin (Plitidepsin)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues